AveXis (NASDAQ:AVXS) will release its earnings data after the market closes on Tuesday, February 27th. Analysts expect AveXis to post earnings of ($1.64) per share for the quarter.
AveXis (AVXS) opened at $121.47 on Monday. AveXis has a 1 year low of $54.11 and a 1 year high of $128.00.
In other news, VP Andrew F. Knudten sold 2,000 shares of the stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $94.48, for a total value of $188,960.00. Following the sale, the vice president now directly owns 7,000 shares of the company’s stock, valued at $661,360. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Sukumar Nagendran sold 1,780 shares of the stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $94.77, for a total transaction of $168,690.60. Following the completion of the sale, the vice president now directly owns 1,780 shares in the company, valued at $168,690.60. The disclosure for this sale can be found here. Over the last three months, insiders sold 57,560 shares of company stock worth $6,160,062. Insiders own 18.60% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This news story was originally posted by Ticker Report and is the property of of Ticker Report. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international copyright laws. The correct version of this news story can be viewed at https://www.tickerreport.com/banking-finance/3222785/avexis-avxs-scheduled-to-post-earnings-on-tuesday.html.
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Receive News & Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related companies with MarketBeat.com's FREE daily email newsletter.